Expert in Due Diligence, Competitive Differentiation, Science Scouting, Innovation Assessment, Research Tools, Expert Witness, Cancer Biomarkers, Cancer Immunology, Assay Development, Research Devices
Expert ID: 724745 California, USA
Oversaw innovation and entrepreneurship at Mitchell Cancer Institute resulting in 5 spin-out biotechnology companies in the area of cancer diagnostics, cancer therapeutics, cancer biomarkers.
Served on technical advisory boards for angel investors, and State-based innovation councils. Provided due diligence reports to equity investors on research-based and clinical devices for cancer detection, diagnosis, and patient stratification.
Expert has 15+ years' experience in the pre-clinical development use of pro-apoptotic methods for the treatment of cancer including gene therapy, cross-linking of pro-apoptotic surface molecules, and combination therapies. She holds 4 patents in this area and has been co-investigator on clinical trials using pro-apoptotic therapy for the treatment of both hematopoietic and non-hematopoietic tumors. She has also been involved in the design and implementation of biomarker studies correlating apoptotic induction and therapeutic outcome.
Expert has 15+ years' experience in pre-clinical development and clinical translation of therapeutics for the treatment of human cancers including lung cancer, head and neck cancers, melanoma, glioma, and non-melanoma skin cancers. Biological therapies include local, intrathecal, and systemic cytokine administration, ex vivo activation of lymphocytes, small molecules, and combination modalities. Her translational research using adenoviral p53-mediated delivery in tumors provided the groundwork for clinical trials in non-small cell lung cancer, multiple patents, and a spin-out company that became publicly traded on the NASDAQ (Introgen Therapeutics). She has collaborated in multiple Phase I, II, and III clinical trials using AdvexinTM and designed and implemented assays supporting phase I and II clinical trials (monitoring and pre-clinical development) and was an advisory board member of the Keck Gene Therapy Center at the University of Texas M.D. Anderson Cancer Center.
Expert has 20+ years' experience in cancer immunology, cancer biology, and cancer research spanning the areas of basic tumor biology, metastasis, apoptosis, skin cancer development, lung cancer therapeutics, gene therapy, vector payload design, cytokine biology, lymphocyte activation, antigen presentation, and immune suppression. She has been actively involved in cancer stem cell isolation and characterization, biomarker discovery for the early detection of ovarian and pancreatic cancer, and drug discovery efforts over the last decade.
Expert has written INDs and served as co-investigator on a number of clinical trials for the treatment of renal cell carcinoma, glioma, melanoma, head and neck cancer, and non-small cell lung cancer. She holds 4 patents related to the induction of apoptosis for the treatment of a variety of human cancers. She has collaborated in multiple Phase I, II, and III clinical trials using AdvexinTM and designed and implemented assays supporting phase I and II clinical trials (monitoring and pre-clinical development) and was an advisory board member of the Keck Gene Therapy Center at the University of Texas M.D. Anderson Cancer Center. Expert was co-investigator on a multi-institutional PO1 grant aimed at the development of novel pro-apoptotic clinical therapies for non-small cell lung cancer. She also has experience in the design of biomarker studies for non-small cell lung cancer clinical trials.She has served as the head of translational sciences for the Mitchell Cancer Institute for the past 8 years.
Expert is designated as a "Skin Cancer Expert" by the American Cancer Society. She has 10+ years of experience in UV-induced carcinogenesis in animal models and her work in this area has been the subject of national and international news reports.Expert has experience in animal models for primary and metastatic melanoma. In addition, she has been co-investigator on a number of clinical trials for the treatment of melanoma using biological therapy and experience with biomarker design in this therapeutic setting.
Expert consulted with a mid-sized biopharmaceutical company on intellectual property strategy and proof-of-principle experiments necessary to advance a pre-clinical cancer therapeutic into clinical development.Expert consulted with a major research University on the development of a new medical school including capital and infrastructure, research hiring and infrastructure, and core laboratory development.Expert consulted with a start-up company on the development of a cancer diagnostic for ovarian cancer.Expert consulted with a start-up company on clinical trial design, collection, and assay development for a cancer diagnostic for pancreatic cancer.Expert consulted with equity investors on market differentiation and barriers to market entry for a novel research assay device,
Expert may consult nationally and internationally, and is also local to the following cities: Mobile, Alabama - Gulfport, Mississippi - Biloxi, Mississippi - Pensacola, Florida
|Year: 1986||Degree: Ph.D.||Subject: Microbiology/Immunology||Institution: University of Oklahoma Health Sciences Center|
|Year: 1979||Degree: B.S.||Subject: Medical Technology||Institution: University of South Alabama|
|Years: 2015 to Present||Employer: Undisclosed||Title: Consultant||Department:||Responsibilities: Provided technical advisory consulting for angel investment group, start-up biotechnology companies in cancer diagnostics and therapeutics.
Expert is self-employed at this life sciences consulting firm.
|Years: 2008 to Present||Employer: Undisclosed||Title: Associate Center Director||Department:||Responsibilities: Key executive leadership position responsible for strategic direction, growth and operations, financial sustainability, compliance, intellectual property development, and facilities/infrastructure supporting the Center for Basic and Translational Sciences at the institute. Chief Scientific Officer of institute responsible for research oversight, graduate training, faculty development/advancement/retention. Oversaw innovation and entrepreneurship development for Center. Provided support for the Center Director on special projects to achieve strategic objectives, policy review, problem solving, and communications to diverse external and internal stakeholders including State and local government, Federal government, Federal agencies, community thought leaders, major donors, for-profit and non-profit institutions, other academic institutions, faculty, staff, trainees, and University leadership.
At this cancer center, Expert's responsibilities fall within the bounds of Basic and Translational Sciences.
|Years: 2006 to 2008||Employer: University of California-Riverside||Title: Special Assistant to the Provost for Health Affairs and Business Development||Department: Office of the Chancellor||Responsibilities: Leadership position responsible for strategic planning and development, financial sustainability, and implementation of new four year medical school campus.
Member of the capital, infrastructure, facilities, and work-force development planning team for a new medical school campus at UCR.
Served as advisor to Chancellor and Provost
Responsible for key stakeholder engagement and integration (University faculty, outside consultants, University leadership, public/private investors)
Team member to evaluate institutional risk and exposure for enterprise development
Led outside business development and enterprise relations for innovative funding models.
|Years: 2003 to 2006||Employer: BioLegend||Title: Founding Director, Reserach and Development||Department: Research and Development||Responsibilities: Key executive leadership position in biotechnology start-up company responsible for strategic planning and development of research product portfolio, development and implementation of technical services department, development of technical and marketing product materials, management of outside stakeholder relationships (business partnerships, pharmaceutical companies, Universities, thought leaders). Responsible for financial sustainability of research enterprise, talent management, compliance.|
|Years: 2001 to 2003||Employer: University of California-Riverside and City of Hope||Title: Professor||Department: Professor, Biomedical Sciences and Immunology||Responsibilities: Led active cancer research laboratory comprised of graduate students, technical staff, postdoctoral fellows, clinical fellows, and visiting scientists. Managed NIH, ACS, and Foundation grant portfolio as principal investigator; multi-center program project grant with University of Texas M.D. Anderson, UCR, and City of Hope. Involved in clinical trials for lung cancer treatment. Taught medical students, graduate students, and undergraduate honor students. Served as thesis advisor for 5 Ph.D. students, served on multiple grant review panels, editorial boards. Invited speaker and panelist for multiple national conferences. Member of UCR Executive Committee, chair of Institutional Animal Care and Use Committee (IACUC), and member of the Biomedical Science Dean's Advisory council and the Chancellor's External Advisory committee.|
|Years: 1991 to 2000||Employer: University of Texas M.D. Anderson Cancer Center||Title: Assistant and Associate Professor||Department: Department of Immunology||Responsibilities: Led active, large cancer research laboratory comprised of graduate students, technical staff, postdoctoral fellows, clinical fellows and visiting scientists. Managed NIH, ACS, and Foundation grant portfolio as principal investigator; multi-center program grants. Involved in clinical trials for lung cancer treatment, kidney cancer treatment, and melanoma. Taught medical students, graduate students. Served as thesis advisor for 5 Ph.D. students, on advisory committees for 65 other students, and NIH training grant faculty in Immunology and Cancer Biology. Served on multiple grant review panels, editorial boards and as member of IRB, IACUC, intellectual property committee, Keck Foundation Gene Therapy Steering Committee, and diversity committee. Invited speaker, panelist, and organizer for multiple national and international conferences. Developed intellectual property leading to the spin-out of a biotechnology company for the treatment of lung cancer, Introgen Therapeutics (became publicly traded company on NASDAQ).
She collaborated in multiple Phase I, II, and III clinical trials using AdvexinTM and designed and implemented assays supporting phase I and II clinical trials (monitoring and pre-clinical development). In addition to gene therapy clinical trials, served as co-investigator on Phase I and II clinical trials involving cytokine therapy while maintaining multiple federal, private and foundation grants to support this research.
|Years: 1986 to 1990||Employer: University of Texas M.D. Anderson Cancer Center||Title: Postdoctoral Fellow/Instructor||Department: Department of Tumor Biology||Responsibilities: Performed basic and translational cancer research in melanoma and glioblastoma. Involved in clinical trials and new drug development. Taught graduate students and medical students.|
|Years: 1996 to 1996||Agency: National Cancer Institute||Role: External Site Reviewer||Description: As a member of the External Site Review Team for the program in Molecular Immunoregulation, Expert made recommendations for
future research directions and funding.
|Years: 1995 to 1995||Agency: National Institutes of Health||Role: Grant Study Section Member||Description: As an ad hoc member of the Experimental Immunology Study Section, Expert was responsible for the review of grant proposals and recommendations for receipt of funding.
|Years: 1995 to 1995||Agency: Vetrans Administration||Role: Study Section Member||Description: As an ad hoc member of the Immunology Grant Study Section, Expert was responsible for the review of grant proposals and recommendations for receipt of funding.
|Years: 1995 to 1995||Agency: National Institutes of Health||Role: Special Review Committee||Description: As a member of a Special Review Committee, Expert conducted a site visit, reviewed grant proposals, and made funding recommendations for a major private research institute program project application.|
|Years||Country / Region||Summary|
|Years: 2003 to 2003||Country / Region: Switzerland||Summary: Swiss Cancer League Cancer grant review panel|
|Years: 2003 to 2003||Country / Region: New Zealand||Summary: New Zealand Cancer Society grant review panel|
|Years: 2005 to 2005||Country / Region: Israel||Summary: Israel Science Foundation grant panelist|
|Associations / Societies|
|American Association for Cancer Research( 1986-present)
Women in Cancer Research (1990- present)
American Women in Science (AWIS)
National and San Diego Chapter (2003-2006)
Vice President, Gulf Coast Chapter (1997-1998)
|Expert has served on the Board of Directors for the American Melanoma Society (2003-2005), the Leading Edge Institute (2010-2014), and as a member of the scientific advisory board for the University of Montana Environmental Health Sciences Institute (2001-2009). She has also served on the scientific advisory board of Signature Biosciences, Inc.(2003), and on the external advisory boards of both the University of Texas M.D. Anderson Cancer Center CML Program Project and MDS, MDS-AML studies (1999-2001) and the Burnham Institute
Program Project grant (2003-present).
She currently serves on the board of Alabama Innovation Council Study Commission (Best Policies and Practices), the Alabama Science and Technology Roadmap for Life Sciences (commissioned by State Governor), the Gulf Coast Angel Network Technical Advisory Council--Biotechnology (2011-present), BioAlabama (2013-present), the Mobile Chamber of Commerce (2014-present), Innovate Mobile--Entrepreneurship (2015-present), and the American Cancer Society (2013-present).
In addition, Expert has experience on Editorial Boards including, The Journal of Experimental Therapeutics and Oncology (2000-2009), Apoptosis (1997-2004), and the Journal of Interferon and Cytokine Biology (1994-2003).
Expert has served a a grant panelist for both national and international awards including the the American Cancer Society
Cancer Immunology and Leukemia, Immunology, and Blood Cells study sections (1996-2002), the Concern Foundation Grant Review Committee (2002-2003), the
American Heart Association, Western States study section (2000-2001), the California Department of Health Services (1998), the
National Cancer Institute Program in Molecular Immunoregulation (External Review Site Visit Team,1996), the National Institutes of Health, (Experimental Immunology, 1995), the Veterans Administration (Immunology, 1995), the National Institutes of Health Special Review Committee Site Visit Team (Burnham Institute, La Jolla, CA, 1995), Pennsylvania Department of Health-Cancer Therapeutics (2012-2014), and the M.D. Anderson Melanoma SPORE internal project review (2010-2014).
|Awards / Recognition|
|Marquis’ Who’s Who in the World (2007-present)
Marquis’ Who’s Who in Science and Engineering (2006-present)
Hall of Fame Inductee, College of Allied Health/Medicine
The University of South Alabama (2005)
Distinguished Scientist and Outstanding Alumni Award The University of South Alabama (2004)
American Cancer Society Experts Directory in Skin Cancer (2000)
John McGovern Award for Outstanding Graduate Teaching The University of Texas M.D. Anderson Cancer Center (1999)
Dean’s Award for Excellence The University of Texas Health Science Center at Houston (1996-1997)
Preuss Foundation Postdoctoral Fellowship Recipient (1986-1989)
Cora M. Downs Award for Outstanding Graduate Research, American Society of Microbiology (1986)
University of Oklahoma Regent's Award Outstanding Graduate Research (1985)
Noble Foundation Predoctoral Fellowship (1982-1986)
National Ames Graduate Scholarship in Immunology (1981)
|Medical / Professional|
|Expert served as a Preuss Foundation fellow with Dr. Elizabeth Grimm at The University of Texas M.D. Anderson Cancer Center.|
|Publications and Patents Summary|
|Expert holds four patents in the area of cancer therapeutics and has published over 80 papers in the area of cancer biology, cancer immunology, metastasis, cancer stem cells, and apoptosis. Her scientific work has been featured on CNN news, BBC Radio, and National Public Radio and has been profiled in the Wall Street Journal, Newsweek, Time, BioWorld Today, NBC, ABC, and BBC news, among others.|
Fields of Expertise
immunoassay, due diligence, technology innovation, strategic differentiation, apoptosis, cell death, gene therapy, adenovirus, biological therapy, cancer, cancer biology, cancer research, immunology, translational medicine, cancer treatment, ultraviolet radiation energy, skin cancer, skin tumor, intellectual property strategy, cancer causation, cancer diagnosis, skin cancer treatment, animal care, gene therapy vector purification, human skin, clinical study, interleukin, education, clinical trial design, polyclonal antibody, basal cell carcinoma, biological response, clinical research, molecular oncology, immunocytochemistry, clinical flow cytometry, immunohistochemistry, adoptive cellular immunotherapy, humoral immunology, cellular immunology, T lymphocyte, cellular immunity, skin, cytotoxic T lymphocyte, clinical trial, clinical medicine, biomarker, antibody production, antibody